Åse Aulie Michelet is CEO in Teres Medical Group AS. She has her education from ETH in Zurich and is Cand. pharm from the University of Oslo. Michelet has long experience from the pharmaceutical industry ; Nycomed, Amersham and GE Healthcare. She has held leading positions in these companies within R&D, marketing and manufacturing. Åse Aulie Michelet has also been CEO in Marine Harvest ASA. She has had many board appointments in Norwegian industrial companies and is currently board member in Cermaq ASA.
Inven2's Board of Directors
Magnus Gulbrandsen is professor at the Centre for Technology, Innovation and Culture at the University of Oslo. For several years he has studied university-industry collaboration, commercialization of research, and various aspects of innovation in Norway and other countries – from entrepreneurship in Berlin to public venture capital in the US. In addition to books and scientific articles, Gulbrandsen has contributed in evaluations and as consultant to Norwegian and international organisations such as the OECD.
Tone Tønjum is professor and consulting physician in clinical microbiology at the University of Oslo and Oslo University Hospital. She was the director of the Centre for Molecular Biology and Neuroscience 2009-2012. Tønjum is the leader of an active research group, and plays a key role in many multidisciplinary research settings. She is member of the Norwegian Academy of Science and Letters, and on the board of a number of international scientific advisory boards. Tønjum studies the role of genome dynamics in disease.
Egil Myklebust is a Bachelor of Law from the University of Oslo. From 1991 to 2001 he worked as General Manager of Norsk Hydro. Egil Myklebust has also been CEO at NHO (The Confederation of Norwegian Enterprise) and Member of the Board at the University of Oslo.
Inger Sandlie is professor of molecular biology and deputy director of the Center for Immune Regulation, University of Oslo. She has a PhD from the University of Bergen and did postdocs at Johns Hopkins University, USA, and the Norwegian National Cancer Hospital. She heads an active research group and is co-inventor of more than 10 patents that describe the production and use of modified antibodies and albumin. Furthermore, she is co-founder of two biotechnology companies, Vaccibody A/S and Nextera A/S, and has an extensive research collaboration with Novozymes A/S. In 2011, she received the first innovation prize awarded by the University of Oslo.
Erlend B. Smeland is director of research, innovation and education at Oslo University Hospital and professor at the University of Oslo. He is a group leader at the Centre for Cancer Biomedicine at the University of Oslo. He has been Head of department at the Institute for Cancer Research at Oslo university Hospital and Head of Research in the South-Eastern Norway Regional Health Authority. Erlend B. Smeland is a member of the Board of Directors of the Norwegian Radium Hospital Research Foundation.
In 2004, Erlend B. Smeland received King Olav V’s Cancer Research Award.
Knut Fægri is currently Vice Rector at UiO. He has a cand. real degree from UiB, and a Dr. Philos. from UiO. He has been with the UiO since 1978, and was appointed professor in 1988. Over a total of more than 20 years he has held various leadership offices at UiO (Dept. Chair, Dean, Prorector). He had also held a number of positions in national and international scientific and admistrative organs. He has experience from previous and present positions on the boards of various scientific institutions.
Kjetil Storvik is head of innovation at Helse Sør-Øst RHF - South Eastern Norway Regional Health Authority. Before he joined Helse Sør-Øst, he was CEO of Swedish-Norwegian Industrial Fund, Nordic Innovation and OREEC – Oslo Renewable Energy and Environment Cluster.
Henning is a lawyer by training and profession, but is now most active as a strategic advisor, investor and board member in Norwegian and international companies. He was for a number of years member of the International Board of DLA Piper, the world largest business law firm. He was also a member of the global management team as Sector Head, global transportation businesses. Henning is Chairman of the Advisory Board of the Nordic Investment company, Ratos AB. Listed on the Stockholm Stock Exchange. He also serves as an Industrial Advisor for Ratos. He holds and has held a number of boardmemberships within businesses as media, investment companies, financial institutions, hospitality, retail and startups. He serves at the Board of the investment company Aars as. Amongst their major holdings are Møllergruppen, the largest car importer and car dealer in the Nordics and the Baltics, Møller Real Estate and the PE company Katalysator. At present he also holds boardmemberships in the investment company Armadillo and the resort developer Koh Tan Resorts. He is Charirman of DLA Pipers Advisory Board and of EIBC (Euro Iran Business Consultants)